Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT00568139
Active, not recruiting Observational

Evaluation of Side Effects of Mitotane

NCT00568139 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Wuerzburg
Phase
Observational
Started
2008-01
Last updated
2026-05-07

Condition(s) studied

Adrenocortical Carcinoma

Study summary

Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adrenocortical carcinoma * Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)

Primary outcome measure(s)

  • Documentation of adverse effects — from starting mitotane until discontinuation of mitotane (since this is very variable from patient to patient no specific number of days or weeks can be entered (standard therapy would be about 2 years) or start of additional other medical therapies
    Adverse effects will be documented using the NCI CTC AE v5.5

Trial sites (1)

FacilityCityRegionStatus
University Hospital Würzburg Germany

More University of Wuerzburg trials in Germany

Registry for Hypoparathyroidism Wuerzburg Recruiting
Adrenal Tumors - Pathogenesis and Therapy Recruiting
Effects of Isolated Lumbar Extension Resistance Training Alone and in Combination with General Exercise and Manual Therapy Active, not recruiting
German Adrenocortical Carcinoma Registry Recruiting
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Active, not recruiting

Other trials for the same condition

Adrenal Tumors - Pathogenesis and Therapy Recruiting
German Adrenocortical Carcinoma Registry Recruiting
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00568139 on ClinicalTrials.gov ↗ ← All trials in Germany